Drug Trial Radar · NCT05663411
A Study of SHR6508 in Secondary Hyperparathyroidism
Last checked: Nov 20, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
75
Actual
Start
Feb 24, 2023
Primary completion
Oct 31, 2023
Study completion Nov 30, 2023
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
Conditions
- Secondary Hyperparathyroidism
Interventions
SHR6508Drug
SHR6508
SHR6508Drug
SHR6508
CinacalcetDrug
Cinacalcet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in serum iPTHTime frame: Baseline and the efficacy period, defined as Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.